Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.69+0.02 (+0.35%)
At close: 04:00PM EST
5.82 +0.13 (+2.28%)
After hours: 04:23PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.17B
Enterprise value 1.61B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)3.38
Price/book (mrq)56.59
Enterprise value/revenue 5.08
Enterprise value/EBITDA -13.14

Trading information

Stock price history

Beta (5Y monthly) 1.87
52-week change 3-48.83%
S&P500 52-week change 315.38%
52-week high 312.08
52-week low 34.83
50-day moving average 35.76
200-day moving average 37.26

Share statistics

Avg vol (3-month) 33.4M
Avg vol (10-day) 35.17M
Shares outstanding 5204.81M
Implied shares outstanding 6204.81M
Float 8174.58M
% held by insiders 11.11%
% held by institutions 188.76%
Shares short (14 Nov 2023) 429.47M
Short ratio (14 Nov 2023) 47.71
Short % of float (14 Nov 2023) 416.01%
Short % of shares outstanding (14 Nov 2023) 414.39%
Shares short (prior month 12 Oct 2023) 444.19M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin -74.43%
Operating margin (ttm)-13.74%

Management effectiveness

Return on assets (ttm)-12.41%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)317.56M
Revenue per share (ttm)1.68
Quarterly revenue growth (yoy)14.40%
Gross profit (ttm)10.94M
EBITDA -105.72M
Net income avi to common (ttm)-236.35M
Diluted EPS (ttm)-1.25
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)397.59M
Total cash per share (mrq)1.94
Total debt (mrq)845.43M
Total debt/equity (mrq)N/A
Current ratio (mrq)5.54
Book value per share (mrq)-2.16

Cash flow statement

Operating cash flow (ttm)-110.07M
Levered free cash flow (ttm)-95.71M